Figure 5

Design of the Phase I clinical trial. Sequential dose and flow rate escalation is presented per group of subjects in the Phase I trial. For the dose escalation, in each group A to G, consisting of eight subjects, six received TRO40303 and two the placebo; flow rate escalation was performed in sub-groups of four subjects. In groups H to K consisting of four subjects, three subjects received TRO40303 and one the placebo.